反応式
[CH2:1]([C:5]1[CH:6]=[CH:7][C:8]([C:11]([OH:13])=O)=[N:9][CH:10]=1)[CH2:2][CH2:3][CH3:4].ClC(OC(C)C)=O.Cl.[CH3:22][S:23]([C:26]1[CH:31]=[CH:30][C:29]([N:32]2[C:36]3=[N:37][CH:38]=[N:39][C:40]([O:41][CH:42]4[CH2:47][CH2:46][NH:45][CH2:44][CH2:43]4)=[C:35]3[CH:34]=[N:33]2)=[CH:28][CH:27]=1)(=[O:25])=[O:24].C(N(CC)CC)C>CN(C=O)C>[CH2:1]([C:5]1[CH:6]=[CH:7][C:8]([C:11]([N:45]2[CH2:46][CH2:47][CH:42]([O:41][C:40]3[N:39]=[CH:38][N:37]=[C:36]4[N:32]([C:29]5[CH:28]=[CH:27][C:26]([S:23]([CH3:22])(=[O:24])=[O:25])=[CH:31][CH:30]=5)[N:33]=[CH:34][C:35]=34)[CH2:43][CH2:44]2)=[O:13])=[N:9][CH:10]=1)[CH2:2][CH2:3][CH3:4]参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
実験手順
5-Butyl-pyridine-2-carboxylic acid (92 mg, 0.51 mmol) and isopropyl chloroformate (70 μL, 0.51 mmol) were dissolved in DMF and stirred at room temperature for 40 min. 1-(4-Methanesulfonyl-phenyl)-4-(piperidin-4-yloxy)-1H-pyrazolo[3,4-d]pyrimidine hydrochloride (70 mg, 0.17 mmol) and triethylamine (72 μL, 0.51 mmol) were added next and continued to stir for 24 hours. Progress of the reaction was monitored by TLC and LCMS. Removal of organic solvents in vacuo and purification by HPLC afforded Compound A125 as a white solid (13 mg, 13%). Exact mass calculated for C27H30N6O4S 534.63, found 535.20 (MH+).
後処理
- stirringto stir for 24 hours
- customRemoval of organic solvents
- customin vacuo and purification by HPLC
出典と根拠
- ORDレコード
- ord-9944c216294d426aa0aa521f149a665f
- 出典データセット
- uspto-grants-2006_11
- 特許番号
- US07132426B2
関連ノート
読み込み中…